Abstract
Rationale
Experimental studies have investigated the effects of chronic donepezil treatment on the behavioral deficits elicited by reduced activity or the loss of cholinergic neurons that occurs in aging or in models of dementia. However, few studies have analyzed the effects of chronic donepezil treatment on the cognitive functions of intact animals.
Objectives
The cognitive functions of healthy young rats treated chronically with the acetylcholinesterase inhibitor donepezil were evaluated using a wide behavioral test battery.
Results
Chronic treatment with donepezil ameliorated memory functions and explorative strategies, speeded up the acquisition of localizing knowledge, augmented responsiveness to the context, and reduced anxiety levels. However, it did not affect spatial span, modify motivational levels, or influence associative learning.
Conclusions
The present findings show the specific profile of donepezil action on cognitive functions in the presence of unaltered cholinergic neurotransmission systems.
Similar content being viewed by others
References
Barnes CA, Meltzer J, Houston F, Orr G, McGann K, Wenk GL (2000) Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 99:17–23
Bartus RT (2000) On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163:495–529
Bartus RT, Dean RL, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 30:408–414
Birks J, Flicker L (2006) Donepezil for mild cognitive impairment. Cochrane Database Syst Rev 193:CD006104
Bontempi B, Whelan KT, Risbrough VB, Lloyd GK, Menzaghi F (2003) Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors. Neuropsychopharmacology 28:1235–1246
Carey GJ, Billard W, Binch H 3rd, Cohen-Williams M, Crosby G, Grzelak M, Guzik H, Kozlowski JA, Lowe DB, Pond AJ, Tedesco RP, Watkins RW, Coffin VL (2001) SCH 57790, a selective muscarinic M(2) receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals. Eur J Pharmacol 431:189–200
Cheng DH, Ren H, Tang XC (1996) Huperzine a novel promising acetylcholinesterase inhibitor. Neuroreport 8:97–101
Davis KL, Mohs RC, Tinklenberg JR, Pfefferbaum A, Hollister LE, Kopell BS (1978) Physostigmine: improvement of long-term memory processes in normal humans. Science 201:272–274
Dawson GR, Iversen SD (1993) The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav Brain Res 57:143–153
Dong H, Csernansky CA, Martin MV, Bertchume A, Vallera D, Csernansky JG (2005) Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer’s disease. Psychopharmacology 181:145–152
Ernst M, Matochik JA, Heishman SJ, Van Horn JD, Jons PH, Henningfield JE, London ED (2001) Effect of nicotine on brain activation during performance of a working memory task. Proc Natl Acad Sci U S A 98:4728–4733
Everitt BJ, Robbins TW (1997) Central cholinergic systems and cognition. Annu Rev Psychol 48:649–684
Federico F, Leggio MG, Neri P, Mandolesi L, Petrosini L (2006) NMDA receptor activity in learning spatial procedural strategies II. The influence of cerebellar lesions. Brain Res Bull 16:356–367
Freo U, Pizzolato G, Dam M, Ori C, Battistin L (2002) A short review of cognitive and functional neuroimaging studies of cholinergic drugs: implications for therapeutic potentials. J Neural Transm 109:857–870
Furey ML, Pietrini P, Haxby JV (2000) Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science 290:2315–2319
Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, Whalen E, Emir B, Donepezil MSAD Study Investigators Group (2002a) Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr 14:389–404
Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P, Donepezil MSAD Study Investigators’ Group (2002b) Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer’s disease. Curr Med Res Opin 18:347–354
Giacobini E, Zhu XD, Williams E, Sherman KA (1996) The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 35:205–211
Gill TM, Sarter M, Givens B (2000) Sustained visual attention performance-associated prefrontal neuronal activity: evidence for cholinergic modulation. J Neurosci 20:4745–4757
Giovannini MG, Casamenti F, Bartolini L, Pepeu G (1997) The brain cholinergic system as a target of cognition enhancers. Behav Brain Res 83:1–5
Gold PE (2003) Acetylcholine modulation of neural systems involved in learning and memory. Neurobiol Learn Mem 80:194–210
Grön G, Kirstein M, Thielscher A, Riepe MW, Spitzer M (2005) Cholinergic enhancement of episodic memory in healthy young adults. Psychopharmacology 182:170–179
Hatip-Al-Khatib I, Iwasaki K, Yoshimitsu Y, Arai T, Egashira N, Mishima K, Ikeda T, Fujiwara M (2005) Effect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats. Br J Pharmacol 145:1035–44
Hernandez CM, Gearhart DA, Parikh V, Hohnadel EJ, Davis LW, Middlemore ML, Warsi SP, Waller JL, Terry AV (2006) Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats. J Pharmacol Exp Ther 316:679–694
Higgins GA, Enderlin M, Fimbel R, Haman M, Grottick AJ, Soriano M, Richards JG, Kemp JA, Gill R (2002) Donepezil reverses a mnemonic deficit produced by scopolamine but not by perforant path lesion or transient cerebral ischaemia. Eur J Neurosci 15:1827–1840
Kirkby DL, Jones DN, Barnes JC, Higgins GA (1996) Effects of anticholinesterase drugs tacrine and E2020, the 5-HT(3) antagonist ondansetron, and the H(3) antagonist thioperamide, in models of cognition and cholinergic function. Behav Pharmacol l7:513–525
Kumari V, Gray JA, ffytche DH, Mitterschiffthaler MT, Das M, Zachariah E, Vythelingum GN, Williams SC, Simmons A, Sharma T (2003) Cognitive effects of nicotine in humans: an fMRI study. Neuroimage 19:1002–1013
Leggio MG, Federico F, Neri P, Graziano A, Mandolesi L, Petrosini L (2006) NMDA receptor activity in learning spatial procedural strategies. I. The influence of hippocampal lesions. Brain Res Bull 16:347–355
Levin ED, Simon BB (1998) Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 138:217–30
Levy ML, Cummings JL, Kahn-Rose R (1999) Neuropsychiatric symptoms and cholinergic therapy for Alzheimer’s disease. Gerontology 45:15–22
Liang YQ, Tang XC (2006) Comparative studies of huperzine A, donepezil, and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats. Acta Pharmacol Sin 27:1127–36
Mandolesi L, Leggio MG, Graziano A, Neri P, Petrosini L (2001) Cerebellar contribution to spatial event processing: involvement in procedural and working memory components. Eur J Neurosci 14:2011–2022
Molinari M, Grammaldo LG, Petrosini L (1997) Cerebellar contribution to spatial event processing: right/left discrimination abilities in rats. Eur J Neurosci 9:1986–1992
Moriguchi S, Zhao X, Marszalec W, Yeh JZ, Narahashi T (2005) Modulation of N-methyl-d-aspartate receptors by donepezil in rat cortical neurons. J Pharmacol Exp Ther 315:125–135
Morris RG, Garrud P, Rawlins JN, O’Keefe J (1982) Place navigation impaired in rats with hippocampal lesions. Nature 297:681–683
Mumenthaler MS, Yesavage JA, Taylor JL, O’Hara R, Friedman L, Lee H, Kraemer HC (2003) Psychoactive drugs and pilot performance: a comparison of nicotine, donepezil, and alcohol effects. Neuropsychopharmacology. 28:1366–1373
Narahashi T, Moriguchi S, Zhao X, Marszalec W, Yeh JZ (2004) Mechanisms of action of cognitive enhancers on neuroreceptors. Biol Pharm Bull 27:1701–1706
Ogura H, Kosasa T, Kuriya Y, Yamanishi Y (2000) Donepezil, a centrally acting acetylcholinesterase inhibitor, alleviates learning deficits in hypocholinergic models in rats. Methods Find Exp Clin Pharmacol 22:89–95
Palmer AM (2002) Pharmacotherapy for Alzheimer’s disease: progress and prospects. Trends Pharmacol Sci 23:426–433
Parent MB, Baxter MG (2004) Septohippocampal acetylcholine: involved in but not necessary for learning and memory? Learn Mem 11:9–20
Pepeu G, Giovannini MG (2004) Changes in acetylcholine extracellular levels during cognitive processes. Learn Mem 11:21–27
Petrosini L, Molinari M, Dell’Anna ME (1996) Cerebellar contribution to spatial event processing: Morris water maze and T-maze. Eur J Neurosci 8:1882–1896
Phillis JW (2005) Acetylcholine release from the central nervous system: a 50-year retrospective. Crit Rev Neurobiol 17:161–217
Poorheidari G, Stanhope KJ, Pratt JA (1998) Effects of the potassium channel blockers, apamin and 4-aminopyridine, on scopolamine-induced deficits in the delayed matching to position task in rats: a comparison with the cholinesterase inhibitor E2020. Psychopharmacology 135:242–255
Prickaerts J, Sik A, van der Staay FJ, de Vente J, Blokland A (2005) Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: acquisition versus consolidation. Psychopharmacology 177:381–390
Rogers SL, Friedhoff LT (1996) The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia 7:293–303
Rogers SL, Doody RS, Mohs RC, Friedhoff LT (1998) Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 158:1021–1031
Rose SP (2002) ‘Smart drugs’: do they work? Are they ethical? Will they be legal? Nat Rev Neurosci 3:975–979
Rupniak NM, Tye SJ, Field MJ (1997) Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology 131:406–410
Sarter M, Givens B, Bruno JP (2001) The cognitive neuroscience of sustained attention: where top-down meets bottom-up. Brain Res Rev 35:146–160
Sarter M, Bruno JP, Givens B (2003) Attentional functions of cortical cholinergic inputs: what does it mean for learning and memory? Neurobiol Learn Mem 80:245–256
Saykin AJ, Wishart HA, Rabin LA, Flashman LA, McHugh TL, Mamourian AC, Santulli RB (2004) Cholinergic enhancement of frontal lobe activity in mild cognitive impairment. Brain 127:1574–1583
Seltzer B (2007) Donepezil: an update. Expert Opin Pharmacother 8:1011–1023
Shearman E, Rossi S, Szasz B, Juranyi Z, Fallon S, Pomara N, Sershen H, Lajtha A (2006) Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study. Brain Res Bull 9:204–213
Shigeta M, Homma A (2001) Donepezil for Alzheimer’s disease: pharmacodynamic, pharmacokinetic, and clinical profiles. CNS Drug Rev 7:353–368
Sonkusare S, Srinivasan K, Kaul C, Ramarao P (2005) Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats. Life Sci 77:1–14
Spowart-Manning L, van der Staay FJ (2004) The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse. Behav Brain Res 151:37–46
Spowart-Manning L, van der Staay FJ (2005) Spatial discrimination deficits by excitotoxic lesions in the Morris water escape task. Behav Brain Res 156:269–276
Sugimoto H (2001) Donepezil hydrochloride: a treatment drug for Alzheimer’s disease. Chem Rec 1:63–73
Sun QQ, Xu SS, Pan JL, Guo HM, Cao WQ (1999) Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students. Zhongguo Yao Li Xue Bao 20:601–603
Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, Akaike A (2003) Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 306:772–777
Tokita K, Yamazaki S, Yamazaki M, Matsuoka N, Mutoh S (2002) Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats. Pharmacol Biochem Behav 73:511–519
van der Staay FJ, Bouger PC (2005) Effects of the cholinesterase inhibitors donepezil and metrifonate on scopolamine-induced impairments in the spatial cone field orientation task in rats. Behav Brain Res 156:1–10
Winstein CJ, Bentzen KR, Boyd L, Schneider LS (2007) Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer’s disease? Curr Alzheimer Res 4:273–276
Wise LE, Iredale PA, Stokes RJ, Lichtman AH (2007) Combination of rimonabant and donepezil prolongs spatial memory duration. Neuropsychopharmacology 32:1805–1812
Yamada K, Takayanagi M, Kamei H, Nagai T, Dohniwa M, Kobayashi K, Yoshida S, Ohhara T, Takuma K, Nabeshima T (2005) Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats. Behav Brain Res 162:191–199
Yesavage JA, Mumenthaler MS, Taylor JL, Friedman L, O’Hara R, Sheikh J, Tinklenberg J, Whitehouse PJ (2002) Donepezil and flight simulator performance: effects on retention of complex skills. Neurology 59:123–125
Zhang L, Zhou FM, Dani JA (2004) Cholinergic drugs for Alzheimer’s disease enhance in vitro dopamine release. Mol Pharmacol 66:538–544
Acknowledgments
Donepezil was generously gifted by Eisai, Inc. This study was supported by MIUR grants to LP. None of the authors has a conflict of interest.
Conflict of interest statement
None of the authors has any conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cutuli, D., Foti, F., Mandolesi, L. et al. Cognitive performance of healthy young rats following chronic donepezil administration. Psychopharmacology 197, 661–673 (2008). https://doi.org/10.1007/s00213-008-1084-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-008-1084-0